SavedAdd your journal

Journals / Eurasian Journal of Pulmonology / 2021 / Cilt: 23 - Sayı: 1

Chemotherapy given lung cancer in intensive care unit

Ayşe Filiz Koşar
Aybüke Kekeçoğlu
Burcu İleri Fikri
Özkan Devran
Pages
72–75
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Chemotherapy was performed for SCLC which is a chemosensitive tumor.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Lung cancer is the leading cause of cancer‑related death among all types of cancers.
📊
Key Findings & Data:In lung cancer patients, hospitalization rates in intensive care units (ICUs) are gradually increasing due to both illness‑ and treatment‑related complications.
💡
Conclusion & Impact:Chemotherapy was performed for SCLC which is a chemosensitive tumor.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Lung cancer is the leading cause of cancer‑related death among all types of cancers. In lung cancer patients, hospitalization rates in intensive care units (ICUs) are gradually increasing due to both illness‑ and treatment‑related complications. A 61‑year‑old male patient who had undergone radiotherapy for small cell lung cancer (SCLC) was admitted to the ICU on the 3rd day of his treatment because of hypercapnic respiratory failure. High‑flow oxygen therapy was started. The mass lesion showed rapid progression. Chemotherapy was performed for SCLC which is a chemosensitive tumor.

🔖

Cite This Article

Koşar, A. F., Kekeçoğlu, A., Fikri, B. İ., Devran, Ö. (2022). Chemotherapy given lung cancer in intensive care unit. Eurasian Journal of Pulmonology, Cilt: 23 - Sayı: 1, 72–75. https://ajindex.com/articles/509576

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed.: American College of Chest Physicians evidence‑based clinical practice guidelines. Chest 2013;143:400‑19
  2. World Health Organization. GLOBOCAN 2012: Estimated Cancer İncidence, Mortality and Prevalence Worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_ cancer. aspx. [Last accessed on 2018 Oct 10]
  3. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975‑ 2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/ posted to the SEER web site, April 2019
  4. Patel T, McGovern EM, Wolfe D, Lewis ME, Chowdhury M. Pharmacologic Considerations in Oncology Critical Care. Oncology Critical Care 2016;35:68. 5. 5Soubani AO, Ruckdeschel JC. The outcome of medical intensive care for lung cancer patients: The case for optimism. J Thorac Oncol 2011;6:633‑8
  5. Azoulay E, Schlemmer B. Diagnostic strategy in cancer patients with acute respiratory failure. Intensive Care Med 2006;32:808‑22
  6. Sztrymf B, Messika J, Bertrand F, Hurel D, Leon R, Dreyfuss D, et al. Beneficial effects of humidified high flow nasal oxygen in critical care patients: A prospective pilot study. Intensive Care Med 2011;37:1780‑6. 8. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small‑cell lung cancer. J Clin Oncol 1999;17:658‑67
  7. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996;32A: 1135‑41
  8. Verger E, Salamero M, Conill C. Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa? Eur J Cancer 1992;28A: 1328‑30
  9. Moors I, Pène F, Lengline É, Benoit D. Urgent chemotherapy in hematological patients in the ICU. Curr Opin Crit Care 2015;21:559‑68.